DOI

  • Tatiana O Kolesnikova
  • David S Galstyan
  • Konstantin A Demin
  • Mikhail A Barabanov
  • Alexander V Pestov
  • Murilo S de Abreu
  • Tatyana Strekalova
  • Allan V Kalueff

BACKGROUND: Cognitive deficits represent an urgent biomedical problem, and are commonly reduced by nootropic drugs. Animal models, including both rodents and zebrafish, offer a valuable tool for studying cognitive phenotypes and screening novel nootropics. Beta-alanine and its derivatives have recently been proposed to exert nootropic activity.

AIMS: This study aimed to characterize putative nootropic profile of a novel β-alanine analogue, 1,3-diaminopropane (MB-005), in adult zebrafish.

METHODS: Nootropic profile of MB-005 was assessed in adult zebrafish in the novel tank and conditioned place aversion (CPA) tests acutely, and in cued-learning plus-maze (PMT) tests chronically.

RESULTS/OUTCOMES: MB-005 did not alter zebrafish anxiety-like behavior or monoamine neurochemistry acutely, improved short-term memory in the CPA test, but impaired cognitive performance in both CPA and PMT tests chronically.

CONCLUSIONS/INTERPRETATION: This study reveals high sensitivity of zebrafish cognitive phenotypes to MB-005, suggesting it as a potential novel cognitive enhancer acutely, but raises concerns over its cognitive (and, possibly, other) side-effects chronically.

Язык оригиналаанглийский
Страницы (с-по)892-902
Число страниц11
ЖурналJournal of Psychopharmacology
Том36
Номер выпуска7
Дата раннего онлайн-доступа17 июн 2022
DOI
СостояниеОпубликовано - июл 2022

    Предметные области Scopus

  • Психиатрия и душевное здоровье
  • Фармакология (медицинская0
  • Фармакология

ID: 96511795